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Pharmacokinetic modelling was used to determine the glomerular filtration rate and tubular secretion of neopterin, a marker for cellular immune 
activation. The method involves parameter identification employing the transient venous plasma concentration profiles of marker substances. By 
combined i.v. injection of neopterin and inulin which is excreted exclusively via glomerular filtration, neopterin was shown to be excreted in addition 
to glomerular filtration, by tubular secretion: clearance of inulin, 112 (S.D. 2.2) ml/liter; clearance of neopterin, 499 (S.D. 79.7) ml/min. A pilot 
experiment using in addition p-amino hippuric acid suggests that neopterin and p-amino hippuric acid may employ the same carrier system for 
tubular secretion. 
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1. INTRODUCTION 
During the past decade, interest in the clinical appli- 
cation of neopterin has greatly increased. Neopterin 
belongs to the class of pteridines which are pyrazino- 
[2,3-d-pyrimidine compounds biosynthesized from 
guanosine triphosphate. Chemically, neopterin is 2- 
amino-3,4-dihydro-4-oxo-6-(1’S,2’R)-1’,2’,3’-trihydroxy- 
propyl-pterin (Fig. 1). It is biosynthesized in relatively 
large amounts by human macrophages upon stimula- 
tion with interferon-y [ 1 J, and measurement of its con- 
centration in various body fluids has been demonstrated 
to be of clinical interest in various diseases; elevated 
neopterin levels are a sensitive marker for the activation 
of cellular immune system [2,3]. 
On the other hand, such knowledge is required for 
proper interpretation of neopterin concentrations in pa- 
tients who in addition to an immunologically mediated 
disease suffer from renal damage. For example, neop- 
terin measurement is widely used to monitor recipients 
of renal allografts [6,7], and one has to be careful in 
differentiating neopterin elevations due to immune acti- 
vation from mere excretion problems. 
After its interferon-y-mediated biosynthesis, neop- 
terin is metabolically stable, and is excreted via the kid- 
neys. The concentration of neopterin is usually deter- 
mined in blood (serum, plasma) or urine, and it depends 
on renal function. Patients with impaired renal function 
show higher neopterin levels in their circulation. In 
urine, due to normal variability of urine density, it is 
usual practice to relate neopterin concentrations to si- 
multaneously determined urinary creatinine levels. 
There are experiments uggesting that neopterin might 
be excreted via tubular secretion in addition to glomer- 
ular filtration [4,5], but precise knowledge on the excre- 
tion kinetics of neopterin is lacking. 
Measurement of creatinine clearance is commonly 
used for determination of renal function but the meth- 
ods has serious drawbacks, and various methods have 
been suggested to oversome these problems, e.g., by 
medication [8]. We recently described an alternative 
way which employs mathematical modelling of tempo- 
ral venous plasma concentration profiles of marker sub- 
stances [9, lo]. This approach enables one to obtain pre- 
cise estimates of the rate constants determining trans- 
port processes of a substance between various body 
compartments and elimination kinetics via the kidneys. 
Linear as well as non-linear kinetics can be modelled by 
this approach. In contrast to more conventional tech- 
niques, the method is based on repeated measurements 
of the time-dependent concentration of marker or test 
substances in venous blood after venous bolus infusion, 
and neither measurements in urine nor collection of 
24-h urine is required. Monte-Carlo simulation is then 
applied to obtain estimation errors of the model para- 
meters determined by this technique in individual sub- 
jects. 
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We use this approach here for determination of the 
detailed elimination kinetics of exogenously adminis- 
tered neopterin. In addition to investigating, with the 
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Fig. 1. Chemical structure of neopterin and p-amino hippuric acid. 
same model, the elimination of two different doses of 
neopterin, we also study the effect of simultaneously 
applying a bolus injection of neopterin together with 
p-amino hippuric acid (Fig. 1) in order to investigate 
whether both substances compete for renal transport. 
2. MATERIAL AND METHODS 
2.1. Subject 
The experiments were all done using one of the authors (G.R.; male, 
37 years, body length 178 cm, body weight 70 kg) as volunteer. The 
subject was clinically healthy at the time of the experiments, and did 
not receive any medication. Nutrition was normal diet. 
2.2. Chemicals 
Synthetic neopterin was obtained from Dr. B. Schircks, Jona, Swit- 
zerland. This product was previously shown to contain no measurable 
endotoxins [l 11. Furthermore, inulin (INUTEST, Laevosan, Linx, 
Austria) which is conveniently measured by a fully enzymatic method, 
p-amino hippuric acid (Nephrotest, Biologische Arbeitsgemeinschaft, 
Lich/Hessen, Germany) and isotonic sodium chloride solution (Heil- 
mittelwerke Wien, Vienna, Austria) were used. 
2.3. Study design 
Three separate xperiments were performed, with more than one 
month interval in between. For each experiment, 10 ml of the inulin 
solution containing 2,500 mg were used. In addition, 10 ml of freshly 
dissolved neopterin in sodium chloride solution were used. In experi- 
ment no. 1 a low neopterin dose was injected, in experiment no. 2 a 
high amount was used. In the third experiment, 10 ml isotonic saline 
containing 2,200 mg of the sodium salt of p-amino hippuric acid were 
additionally applied. 
The subject, after acquiring a lying position for 30 min before the 
experiment, received the substances by bolus injection into the right 
cubital vein during the initial five min of each experiment, and blood 
samples were then drawn from an intravenous catheter placed in the 
left cubital vein in 5-min intervals during the subsequent two h. An 
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extra blood sample was drawn immediately before injection of test 
substances in order to obtain a base line value of endogenous neop- 
term. 
2.4. Pharmacokinetics 
The model used is the basic model of pharmacokinetics [12] which 
was used either in the linear version, or was adapted in order to allow 
modelling of non-linear effects resulting from capacity-limited tubular 
secretion when using high doses of markers which are transported by 
the tubular anion carrier system, such as p-amino hippuric acid. This 
is of relevance due to the limited number of carriers involved in the 
secretory process. Secretion is furthermore inhibitable by competition 
of many endogenous and exogenous ubstances employing the same 
carrier system as transport mechanism. 
The model equations employed for mathematical modelling are 
described fully elsewhere [9,10]. 
For inulin which is known to be excreted by glomerular filtration 
only, and for neopterin of which rather low absolute amounts were 
used, the full model was simplified by assuming that the simple linear 
two-compartment model is appropriate for which analytic solutions 
of the differential equations are well-known. For p-amino hippuric 
acid, however, a high dosis was used, and the full non-linear model 
was employed in order to deal correctly with the non-linear behavior. 
For the numerical integration of the non-linear system, the fourth- 
order Runge-Kutta technique was used. Fitting of this model to the 
measured concentration data was done by a method of direct search 
employing steepest-descent technique to locate the minimum of the 
error function, defined by the residuals of the fit. 
Measured data are subject to different kinds of errors. Thus, the 
fitted model parameters are associated with estimation errors. In order 
to gain estimates for these parameter errors, after fitting the original 
data repeated runs of the parameter identification procedure were 
performed using artificial protocols. These were produced by super- 
position of Gaussian random numbers on the theoretical trajectory. 
The random numbers were taken from a hypothetical normal distribu- 
tion with mean zero and standard eviation defmed by the experimen- 
tally obtained error function [13] (‘Monte-Carlo technique’). 
3. RESULTS 
Table I shows the clearance values for neopterin and 
inulin obtained from two experiments using different 
doses of neopterin. As Table I shows, the inulin clear- 
ance as a measure of glomerular filtration rate lies in the 
normal range for healthy individuals. The values esti- 
mated for neopterin indicate that in accordance with 
previous findings, neopterin is excreted both by glomer- 
ular filtration and tubular secretion. The clearance val- 
ues appear to be insensitive to variation of injected ne- 
opterin dose. 
Table I 
Results of mathematical modelling of renal excretion kinetics 
Experiment 
Low neopterin High neopterin 
Inulin dose (mg) 2,500 2,500 
Inulin clearance (mVmin) 111.5 (2.2)* 139.7 (2.3) 
Neopterin dose (nmol) 400 3,300 
Neopterin clearance (mUmin) 498.8 (79.7) 498.1 (23.1) 
*SD. given in parentheses. 
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Fig. 2. Temporal venous concentration profiles for inulin, neopterin 
and p-amino hippuric acid after simultaneous i.v. bolus injection. 
Indicated are the measured concentration values (denoted by symbols) 
and the fitted model curves (denoted by the lines). Notably, the con- 
centration profiles of inulin and neopterin were treated by a linear 
model, whereas the elimination kinetics ofp-amino hippuric acid was 
modelled by the full non-linear formalism. The renal clearance values 
estimated from the model were: inulin, 152.8 ml/min (SD. 2.7); neop- 
term, 300.4 (65.3); and PAH, 934.7 (59.3). 
Fig. 2 shows fitted model trajectories together with 
measured temporal concentration profiles for the third 
experiment in which inulin (2,500 mg), neopterin (4,000 
nmol) and the sodium salt of p-amino hippuric acid 
(PAH, 2,200 mg) were injected in combination. The 
clearance for p-amino hippuric acid as an index of renal 
plasma flow lies in a range indicating normal renal func- 
tion [ 141. The markedly lower neopterin clearance value 
observed in this experiment seems to demonstrate that 
p-amino hippuric acid may significantly depress renal 
clearance of neopterin, at least if applied in high dosage. 
4. DISCUSSION 
The precise determination of the elimination kinetics 
of exogenous and endogenous substances by the kid- 
neys is of considerable interest, both for diagnostic and 
therapeutic purposes. We investigate here the possibility 
of applying pharmacokinetic modelling to study the 
renal handling of neopterin, an endogenous marker 
substance which has become widely accepted as a sensi- 
tive indicator for the activation of cell-mediated immu- 
nity in vivo. 
The data presented here fully confirm the existence of 
tubular transport of neopterin which was expected from 
previous observations [4,5]. Notably, the data were ob- 
tained by studying a healthy subject; thus, the result is 
not biased by the presence of a disease. We are, of 
course, aware of the fact that a study on one individual 
only limits the representativity of the results. The rea- 
sons for this limitation are the following: since the 
method used is an invasive one, it is not easy to recruit 
volunteers. Moreover, at the time when the measure- 
ments described here were done, it was generally 
thought that neopterin is biologically inactive [I I]. 
Meanwhile it was found that neopterin enhances the 
toxicity mediated by reactive oxygen and chloride spe- 
cies [I 51. Therefore, obtaining ethical approvement for 
investigating further subjects by bolus injection of neop- 
term would be difficult. On the other hand, although 
measurements were done on a single individual only, 
they are likely to be representative since’(i) there is a 
good agreement with expectation from previous, albeit 
incomplete data [4,5], and (ii), data obtained after bolus 
injection of two different amounts of neopterin show 
excellent accordance (see Table I). Moreover, the 
Monte-Carlo approach used enables statistically correct 
judgement of the precision of the data obtained from the 
experiments. 
The amounts of neopterin injected in the described 
experiments may appear low when compared with inu- 
lin or p-amino hippuric acid. It should be noted in this 
respect, however, that the concentrations of neopterin 
which are constitutively found in healthy humans (i.e. 
in the absence of immunological stimulation), are in the 
range below 10 nmol/l [2,3], and thus are considerably 
lower than the peak values observed after bolus injec- 
tion of the neopterin amounts employed. 
A possible application of the pharmacokinetic ap- 
proach presented here is the investigation of competitive 
interactions between drugs excreted by the renal tubular 
system [16]. In the particular example of neopterin, the 
consideration of such a competitive inhibition of tubu- 
lar secretion appears to be of immediate relevance, since 
neopterin concentrations are widely used to aid in the 
prognosis of patients infected with the human immu- 
nodeficiency virus type 1 (HIV- 1) [ 17-221, and the mod- 
ified nucleosides frequently used for treatment of such 
patients are known to be eliminated, at least partly, via 
the same mechanism [23]. Thus, detailed investigation 
of such putative interactions seems most relevant in 
order to allow proper interpretation of measured serum 
neopterin concentrations in such patients. 
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